Exelixis Eyes Turning Point as Colorectal Cancer Drug Decision Nears

Exelixis (NASDAQ:EXEL) is preparing for a potential regulatory decision on zanzalintinib in colorectal cancer as it seeks to expand beyond its established CABOMETYX franchise, an executive said at the UBS Global Biopharma Conference in London.

Andrew Peters, Exelixis’ senior vice president of strategy and investor relations, said the company is focused on sustaining CABOMETYX sales, preparing for a potential zanzalintinib launch and advancing its pipeline while managing expenses. A regulatory decision on zanzalintinib, also called Zanza, is expected early next year, he said.

“It is kind of that pivot point or turning point for the company as we are transitioning from a single-product company with CABOMETYX to now a multi-franchise company,” Peters said, referring to the potential approval.

Colorectal Cancer Launch Plans

Exelixis has sought approval for zanzalintinib in combination with atezolizumab in previously treated colorectal cancer. Peters said the phase 3 study showed patients in the overall study population lived longer on the combination than on the standard of care.

Asked whether the potential label could be limited based on whether patients had liver metastases, Peters declined to speculate. He said the population included in the company’s filing covered patients with and without liver metastases, and that the study showed consistency of effect across subgroups.

Peters estimated the later-line colorectal cancer market at about $1.5 billion, based on the number of drug-treated patients, assumed treatment duration and contemporary pricing. He said Exelixis intends to compete for share across existing treatment categories and highlighted the combination as a potential chemotherapy-free option.

The company expanded its commercial organization earlier this year to support the CABOMETYX launch in neuroendocrine tumors and prepare for zanzalintinib, Peters said. He added that Exelixis expects to be ready to launch immediately following an approval.

Kidney Cancer Development

Exelixis has seven pivotal studies in its first wave of zanzalintinib development and is planning a second wave, Peters said. He identified a planned first-line renal cell carcinoma study as a key part of that next group of opportunities.

Peters also pointed to two pivotal studies being run by Merck that combine zanzalintinib with belzutifan. He said one is aimed at patients whose cancer returns after adjuvant treatment, while the other addresses a later-line setting.

For a separate non-clear cell renal cell carcinoma study, Exelixis expects a first-quarter topline readout, Peters said. The timeline depends on reaching the required number of events and completing data cleaning. He declined to speculate on the results or whether they would be presented at a particular conference.

CABOMETYX Outlook

In neuroendocrine tumors, Peters said the company’s aspirational peak sales goal remains approximately $400 million, although the launch may take a different shape than initially expected. He attributed the timing to the slower-growing nature of the disease, which can mean longer intervals between scans and treatment changes.

Peters estimated the second-line and later-line oral neuroendocrine tumor market at approximately $1 billion. He said Exelixis is seeking to capture as much share as possible.

On generic competition for CABOMETYX, Peters said the company manages its business using Jan. 1, 2031, as its best estimate for generic availability. He declined to discuss potential legal strategy concerning other challengers.

About Exelixis (NASDAQ:EXEL)

Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.